Sections

Help for women suffering from diminished sex drive

The Brooklyn Paper
Share on TwitterTweet
Share on Facebook
Subscribe

Don’t miss our updates:

One issue that often is overlooked is the importance of sexual intimacy. It may be surprising to know that approximately 40 million American women suffer from some type of sexual disorder — the most common being Hypoactive Sexual Desire Disorder (HSDD), sometimes referred to as low sex drive.

BioSante Pharmaceuti-cals, Inc. is currently sponsoring a nationwide medical research study, the Bloom Study, to determine if LibiGel®, an investigational study medication, can increase women’s sexual desire.

“We know there is a tremendous medical need to address women suffering with low sexual desire,” said James A. Simon, MD, a LibiGel study investigator, clinical professor of Obstetrics and Gynecology at the George Washington University in Washington, DC, medical director at The Women’s Health Research Center in Laurel, Maryland and past president of the North American Menopause Society. “Currently, there are no medications approved by the US Food and Drug Administration (FDA) for the treatment of low sexual desire.”

Sexual activity has many health benefits and is an important part of relationships. But those with HSDD are rarely in the mood for intimacy. For women who have gone through menopause either naturally or after surgery, a decrease in the production of natural testosterone may occur. Testosterone is a hormone that affects many things, including sex drive. The reduction in testosterone may contribute to the symptoms of HSDD, a common condition defined as the persistent lack of sexual desire. And this decrease in sex drive can result in personal distress and interpersonal problems.

The Bloom Study is currently looking for Brooklyn area women at least 30 years of age who have lost their sex drive. Qualified participants must have either gone through menopause or had their ovaries removed. The study is examining the safety and effectiveness of the investigational medication, LibiGel, for the treatment of HSDD. The investigational medication is applied daily to the skin on a woman’s upper arm.

The Bloom Study is taking place in Brooklyn and other cities across the United States. For more on the Bloom Study, visit www.bloomstudy.com or call 1-877-BLOOM-81.

Updated 11:48 am, January 16, 2019
Today’s news:
Share on TwitterTweet
Share on Facebook
Subscribe

Don’t miss our updates:


Reasonable discourse

Comments closed.

First name
Last name
Your neighborhood
Email address
Daytime phone

Your letter must be signed and include all of the information requested above. (Only your name and neighborhood are published with the letter.) Letters should be as brief as possible; while they may discuss any topic of interest to our readers, priority will be given to letters that relate to stories covered by The Brooklyn Paper.

Letters will be edited at the sole discretion of the editor, may be published in whole or part in any media, and upon publication become the property of The Brooklyn Paper. The earlier in the week you send your letter, the better.

Keep it local!

Stay in touch with your community. Subscribe to our free newsletter: